Brito A R
Department of Physiology, UNICAMP, São Paulo, Brazil.
J Ethnopharmacol. 1996 Nov;54(2-3):131-8. doi: 10.1016/s0378-8741(96)01460-2.
This paper presents a reflection based on 15 years' experience of studies on the pharmacology of medicinal plants in an underdeveloped country, Brazil. In these countries the investment in research is small and frequently interrupted. There is no new-medicines development program. Brazilian pharmaceutical companies have been short-sighted and have not developed new drugs. Although the diversity of the Brazilian flora is a remarkable opportunity for the development of new medicine products, natural product research is limited to a small group. These difficulties are common to all underdeveloped countries. Strategies for the pharmacological study of medicinal plants are proposed, the main difficulties are identified and a discussion of possible ways to overcome them is presented.
本文基于在巴西这个欠发达国家开展药用植物药理学研究15年的经验进行反思。在这些国家，对研究的投入很少且经常中断。没有新药开发项目。巴西的制药公司目光短浅，没有开发新药。尽管巴西植物群的多样性为开发新药产品提供了显著机遇，但天然产物研究仅限于一小部分人。这些困难在所有欠发达国家都很常见。本文提出了药用植物药理学研究的策略，指出了主要困难，并讨论了克服这些困难的可能途径。
